Related Experiment Video
Updated: Apr 6, 2026
04:59
Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors
Published on: September 27, 2019
13.3K
Characterization and Validation of a Canine Pruritic Model
Gunnar A K Aberg1, Nada Arulnesan2, Gordon T Bolger2
1Bridge Pharma Inc., 902 Contento Street, Sarasota, FL, USA.
Drug Development Research
|July 30, 2015
Summary
A new canine model for pruritus (itching) was developed using chloroquine (CQ). This validated model effectively tests antipruritic drugs, showing reduced scratching with tested compounds.
Area of Science:
- Veterinary Dermatology
- Preclinical Research Models
Background:
- Canine pruritus mechanisms are poorly understood, limiting effective treatment development.
- Existing models for canine pruritus are scarce due to difficulties in inducing itch reliably.
Purpose of the Study:
- To establish a reliable canine model for inducing pruritus.
- To utilize this model for evaluating the efficacy of antipruritic compounds.
Main Methods:
- Intravenous administration of chloroquine (CQ) to induce pruritus in dogs.
- Validation of the model through a blinded cross-over study using reference drugs (oclacitinib, prednisolone) and a novel compound (norketotifen).
- Quantification of scratching events to assess antipruritic activity.
Main Results:
- Chloroquine reliably induced pruritus in all dogs tested, establishing a viable canine pruritus model.
- Oclacitinib, prednisolone, and norketotifen all demonstrated antipruritic effects, reducing CQ-induced scratching.
- Norketotifen showed a dose-dependent inhibition of scratching, confirming the model's sensitivity.
Conclusions:
- The developed canine pruritus model using chloroquine is effective and reliable for preclinical assessment of antipruritic agents.
- This model provides a valuable tool for advancing the development of new treatments for canine pruritus.
- The study successfully demonstrated the antipruritic potential of norketotifen in a preclinical setting.
